Archives of Neuroscience

Published by: Kowsar

Follow-up Case Report: Bumetanide Can Control Seizural Activity in Temporal Lobe Epilepsy Patient

Zeinab Gharaylou 1 , Abbas Tafakhori 2 , Masoumeh Rostampour 3 and Mahmoudreza Hadjighassem 4 , *
Authors Information
1 International Campus, Tehran University of Medical Sciences, Tehran, IR Iran
2 Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, IR Iran
3 Department of Medical Physics and Biomedical Engineering, Faculty of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
4 Brain and Spinal Cord Injury Research Center, Department of Neuroscience, School of Advanced Technologies in Medicine, International Campus, Tehran University of Medical Sciences, Tehran. IR Iran
Article information
  • Archives of Neuroscience: October 2017, 4 (4); e58681
  • Published Online: September 26, 2017
  • Article Type: Case Report
  • Received: July 24, 2017
  • Accepted: September 11, 2017
  • DOI: 10.5812/archneurosci.58681

To Cite: Gharaylou Z, Tafakhori A, Rostampour M, Hadjighassem M. Follow-up Case Report: Bumetanide Can Control Seizural Activity in Temporal Lobe Epilepsy Patient, Arch Neurosci. 2017 ; 4(4):e58681. doi: 10.5812/archneurosci.58681.

Abstract
Copyright © 2017, Archives of Neuroscience. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Introduction
2. Case Presentation
3. Discussion
References
  • 1. Goldenberg MM. Overview of drugs used for epilepsy and seizures: etiology, diagnosis, and treatment. P T. 2010; 35(7): 392-415[PubMed]
  • 2. Jardim AP, Neves RS, Caboclo LO, Lancellotti CL, Marinho MM, Centeno RS, et al. Temporal lobe epilepsy with mesial temporal sclerosis: hippocampal neuronal loss as a predictor of surgical outcome. Arq Neuropsiquiatr. 2012; 70(5): 319-24[PubMed]
  • 3. Thom M, Liagkouras I, Elliot KJ, Martinian L, Harkness W, McEvoy A, et al. Reliability of patterns of hippocampal sclerosis as predictors of postsurgical outcome. Epilepsia. 2010; 51(9): 1801-8[DOI][PubMed]
  • 4. Loscher W, Puskarjov M, Kaila K. Cation-chloride cotransporters NKCC1 and KCC2 as potential targets for novel antiepileptic and antiepileptogenic treatments. Neuropharmacology. 2013; 69: 62-74[DOI][PubMed]
  • 5. Marguet SL, Le-Schulte VT, Merseburg A, Neu A, Eichler R, Jakovcevski I, et al. Treatment during a vulnerable developmental period rescues a genetic epilepsy. Nat Med. 2015; 21(12): 1436-44[DOI][PubMed]
  • 6. Deidda G, Parrini M, Naskar S, Bozarth IF, Contestabile A, Cancedda L. Reversing excitatory GABAAR signaling restores synaptic plasticity and memory in a mouse model of Down syndrome. Nat Med. 2015; 21(4): 318-26[DOI][PubMed]
  • 7. Sivakumaran S, Maguire J. Bumetanide reduces seizure progression and the development of pharmacoresistant status epilepticus. Epilepsia. 2016; 57(2): 222-32[DOI][PubMed]
  • 8. Eftekhari S, Mehvari Habibabadi J, Najafi Ziarani M, Hashemi Fesharaki SS, Gharakhani M, Mostafavi H, et al. Bumetanide reduces seizure frequency in patients with temporal lobe epilepsy. Epilepsia. 2013; 54(1)-12[DOI][PubMed]
  • 9. Damier P, Hammond C, Ben-Ari Y. Bumetanide to Treat Parkinson Disease: A Report of 4 Cases. Clin Neuropharmacol. 2016; 39(1): 57-9[DOI][PubMed]
  • 10. Vasta R, Caligiuri ME, Labate A, Cherubini A, Mumoli L, Ferlazzo E, et al. 3-T magnetic resonance imaging simultaneous automated multimodal approach improves detection of ambiguous visual hippocampal sclerosis. Eur J Neurol. 2015; 22(4): 725[DOI][PubMed]
  • 11. Kahle KT, Staley KJ. The bumetanide-sensitive Na-K-2Cl cotransporter NKCC1 as a potential target of a novel mechanism-based treatment strategy for neonatal seizures. 2008;
  • 12. Lemonnier E, Lazartigues A, Ben-Ari Y. Treating Schizophrenia With the Diuretic Bumetanide: A Case Report. Clin Neuropharmacol. 2016; 39(2): 115-7[DOI][PubMed]
  • 13. Bruining H, Passtoors L, Goriounova N, Jansen F, Hakvoort B, de Jonge M, et al. Paradoxical Benzodiazepine Response: A Rationale for Bumetanide in Neurodevelopmental Disorders? Pediatrics. 2015; 136(2)-43[DOI][PubMed]
  • 14. Huberfeld G, Wittner L, Clemenceau S, Baulac M, Kaila K, Miles R, et al. Perturbed chloride homeostasis and GABAergic signaling in human temporal lobe epilepsy. J Neurosci. 2007; 27(37): 9866-73[DOI][PubMed]
  • 15. Miles R. Chloride homeostasis and GABA signaling in temporal lobe epilepsy. 2012;
  • 16. Grandgeorge M, Lemonnier E, Degrez C, Jallot N. The effect of bumetanide treatment on the sensory behaviours of a young girl with Asperger syndrome. BMJ Case Rep. 2014; 2014[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments